Technical Analysis for ZYME - Zymeworks Inc.

Grade Last Price % Change Price Change
D 10.71 -0.93% -0.10
ZYME closed down 0.93 percent on Monday, March 18, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
Oversold Stochastic Weakness 0.00%
Spinning Top Other -0.93%
Calm After Storm Range Contraction -0.93%
NR7 Range Contraction -0.93%
Oversold Stochastic Weakness -0.93%
Calm After Storm Range Contraction -0.56%
Outside Day Range Expansion -0.56%
Oversold Stochastic Weakness -0.56%
MACD Bearish Centerline Cross Bearish -0.37%
Calm After Storm Range Contraction -0.37%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 17 hours ago
Down 3% about 19 hours ago
Lower Bollinger Band Support about 19 hours ago
Fell Below Previous Day's Low about 19 hours ago
Down 2 % about 19 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Zymeworks Inc. Description

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Immune System Cancer Immunotherapy Monoclonal Antibodies Antibody Toxins Glycoproteins Her2 Protein Engineering Biological Systems Bispecific Monoclonal Antibody

Is ZYME a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.14
52 Week Low 6.015
Average Volume 403,721
200-Day Moving Average 8.69
50-Day Moving Average 11.23
20-Day Moving Average 11.70
10-Day Moving Average 11.20
Average True Range 0.53
RSI (14) 39.76
ADX 28.89
+DI 13.06
-DI 23.62
Chandelier Exit (Long, 3 ATRs) 11.55
Chandelier Exit (Short, 3 ATRs) 12.04
Upper Bollinger Bands 13.03
Lower Bollinger Band 10.37
Percent B (%b) 0.13
BandWidth 22.81
MACD Line -0.15
MACD Signal Line 0.05
MACD Histogram -0.2032
Fundamentals Value
Market Cap 749.72 Million
Num Shares 70 Million
EPS 3.23
Price-to-Earnings (P/E) Ratio 3.32
Price-to-Sales 1.77
Price-to-Book 1.89
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.39
Resistance 3 (R3) 11.37 11.14 11.27
Resistance 2 (R2) 11.14 10.96 11.14 11.23
Resistance 1 (R1) 10.92 10.86 10.81 10.94 11.20
Pivot Point 10.69 10.69 10.63 10.69 10.69
Support 1 (S1) 10.47 10.51 10.36 10.49 10.22
Support 2 (S2) 10.24 10.41 10.24 10.19
Support 3 (S3) 10.02 10.24 10.15
Support 4 (S4) 10.04